MRIGlobal Partners with NIAID in Tuberculosis Research
Tuberculosis (TB) is a global health emergency and is one of the top 10 causes of death worldwide. Each year, tens of millions of adults and children fall ill, and more than a million die. While treatments are available, continued research is needed to address this public health crisis and health security threat.
The National Institutes of Health: Division of AIDS (NIH-DAIDS) oversees the Mycobacterium tuberculosis (Mtb) Quality Assessment Program (TBQA). The TBQA program supports NIAID clinical studies by providing Mycobacterium tuberculosis (Mtb) specific laboratory QA, evaluation of technologies and specimen processes, technology specific advice and training materials for clinical staff, and disseminates TBQA technical and scientific data. Mtb testing involves millions of patient samples across clinical sites that vary wildly in capability and training. The quality of Mtb testing, including protocol development and quality monitoring is critical to data integrity and success of the clinical studies.
As a partner in this work, MRIGlobal evaluates Mtb technologies and specimen-specific protocols to be used in NIAID-supported clinical investigations and disseminates TBQA technical and scientific data. Further, as multidrug-resistant Mtb continues to grow, we have researched identification of resistance genotypes. We also work with the NIAID laboratory network to review protocols and provide instrumentation validation panels so that labs can demonstrate their ability to accurately and reliably perform study-specific Mtb tests. Additionally, we are conducting a longitudinal data monitoring study to evaluate study data to look for trends or identify areas of improvement. As deficiencies are identified, our experts advise and provide protocol suggestions and training tools to the labs. This broad base of support allows the TBQA program to navigate the complex global landscape, relationships, and dynamically shifting field of TB clinical and laboratory work.’
Getting started with MRIGlobal
Contact MRIGlobal to further understand our work in infectious diseases. We offer a broad portfolio of infectious disease testing assays and capabilities across diagnostic disciplines, from screening and diagnosis to genotyping, therapy, and monitoring. Those seeking analysis of infectious disease tests can trust in our breadth of experience and knowledge – not just on the subject matter, but FDA protocols as well.
As a not-for-profit contract research organization, we have proven ourselves as an objective partner driven to make our clients’ products more successful. We specialize in defense, human health, pharmaceutical sciences, in-vitro diagnostics, energy and environment, agriculture, and global health.
To learn more about the work we’ve done or how we can help you, contact us today. If you are part of an agency, business, or academic institution seeking assistance with a project, use our Project Quote Tool to get started.
Sign up for our newsletter
Sign up for the MRIGlobal newsletter! It’s the best way to get the latest updates in the world of applied scientific engineering research delivered directly to your inbox.